Catalytic action of azolium salts. IX. Synthesis of 6-aroyl-9H-purines and their analogues by nucleophilic aroylation catalyzed by imidazolium or benzimidazolium salt

Chemical and Pharmaceutical Bulletin

Volumn 46, Issue 3, 1998, Pages 390-399

  Miyashita, Akira ^a   Suzuki, Yumiko ^a   Iwamoto, Ken Ichi ^a   Higashino, Takeo ^a  

^a UNIVERSITY OF SHIZUOKA   (Japan)

Author keywords

6 aroyl 9 phenyl 9H purine; Arenecarbaldehyde; Benzimidazolium salt; Catalytic aroylation; Fused aroylpyrimidine; Imidazolium salt

Indexed keywords

6 AROYL 9 PHENYL 9H PURINE; BENZIMIDAZOLE DERIVATIVE; IMIDAZOLE DERIVATIVE; PURINE DERIVATIVE; UNCLASSIFIED DRUG;

ANALYTIC METHOD; ARTICLE; CARBON NUCLEAR MAGNETIC RESONANCE; CATALYSIS; DERIVATIZATION; DRUG SYNTHESIS; HYDROGEN BOND; NONHUMAN;

EID: 0031979762     PISSN: 00092363     EISSN: None     Source Type: Journal    
DOI: 10.1248/cpb.46.390     Document Type: Article

References (25)

1. Part VIII: Miyashita A., Suzuki Y., Ishiguro C., Nagasaki I., Iwamoto K., Higashino T., Chem. Pharm. Bull., 45, 1254-1258 (1997).
2. Shae G., "Comprehensive Heterocyclic Chemistry," Vol. 5, ed. by Katritzky A. R., Rees C. W., Pergamon Press, 1984, pp. 499-605.
3. a) Miyashita A., Matsuda H., Iijima C., Higashino T., Chem. Pharm. Bull., 38, 1147-1152 (1990);
4. b) Idem, ibid., 40, 43-48 (1992);
5. c) Miyashita A., Matsuda H., Higashino T., ibid., 40, 2627-2631 (1992);
6. d) Miyashita A., Matsuda H., Suzuki Y., Iwamoto K., Higashino T., ibid., 42, 2017-2022 (1994);
7. e) Miyashita A., Matsuda H., Matsuoka Y., Iwamolo K., Higashino T., Heterocycles, 40, 653-660 (1995).
8. a) Hayashi E., Shimada N., Yakugaku Zasshi. 99, 201-204 (1979);
9. b) Miyashita A., Suzuki Y., Ohta K., Higashino T., Heterocycles, 39, 345-356 (1994).
10. a) Higashino T., Yoshida S., Hayashi E., Chem. Pharm. Bull., 30, 4521-4525 (1982);
11. b) Cohen S., Thom E., Bendich A., J. Org. Chem., 28, 1379-1383 (1963);
12. c) Giner-Sorolla A., Zimmerman I., Bendich A., J. Am. Chem. Soc., 81, 2515-2521 (1959).
13. Higashino T., Takemoto M., Miyashita A., Hayashi E., Chem. Pharm. Bull., 33, 1395-1399 (1985).
14. a) Cheng C. C., Robins R. K., J. Org. Chem., 21, 1240-1256 (1956);
15. b) Idem, ibid., 23, 191-200 (1958).
16. The calculations were performed with MOPAC Ver 6.0 (PM3) on a Cash system (Sony Techtronix).
17. For example, the reactivities of heteroarenes, including fused halopyrimidines, with phenylacetonitrile have been described in the following references: a) Higashino T., Iwai Y., Eisaku H., Yakugaku Zasshi, 96, 1352-1356 (1976); b) Higashino T., Katori T., Eisaku H., ibid., 99, 1031-1036 (1979); c) Hayashi E., Shimada N., Watanabe K., ibid., 99, 205-206 (1979); d) Yamanaka H., Ohba S., Heterocycles, 31, 895-909 (1990); e) Mizuno Y., Adachi K., Ikeda K., Chem. Pharm. Bull., 2, 225-234 (1954).
18. For example, the reactivities of heteroarenes, including fused halopyrimidines, with phenylacetonitrile have been described in the following references: a) Higashino T., Iwai Y., Eisaku H., Yakugaku Zasshi, 96, 1352-1356 (1976); b) Higashino T., Katori T., Eisaku H., ibid., 99, 1031-1036 (1979); c) Hayashi E., Shimada N., Watanabe K., ibid., 99, 205-206 (1979); d) Yamanaka H., Ohba S., Heterocycles, 31, 895-909 (1990); e) Mizuno Y., Adachi K., Ikeda K., Chem. Pharm. Bull., 2, 225-234 (1954).
19. For example, the reactivities of heteroarenes, including fused halopyrimidines, with phenylacetonitrile have been described in the following references: a) Higashino T., Iwai Y., Eisaku H., Yakugaku Zasshi, 96, 1352-1356 (1976); b) Higashino T., Katori T., Eisaku H., ibid., 99, 1031-1036 (1979); c) Hayashi E., Shimada N., Watanabe K., ibid., 99, 205-206 (1979); d) Yamanaka H., Ohba S., Heterocycles, 31, 895-909 (1990); e) Mizuno Y., Adachi K., Ikeda K., Chem. Pharm. Bull., 2, 225-234 (1954).
20. For example, the reactivities of heteroarenes, including fused halopyrimidines, with phenylacetonitrile have been described in the following references: a) Higashino T., Iwai Y., Eisaku H., Yakugaku Zasshi, 96, 1352-1356 (1976); b) Higashino T., Katori T., Eisaku H., ibid., 99, 1031-1036 (1979); c) Hayashi E., Shimada N., Watanabe K., ibid., 99, 205-206 (1979); d) Yamanaka H., Ohba S., Heterocycles, 31, 895-909 (1990); e) Mizuno Y., Adachi K., Ikeda K., Chem. Pharm. Bull., 2, 225-234 (1954).
21. For example, the reactivities of heteroarenes, including fused halopyrimidines, with phenylacetonitrile have been described in the following references: a) Higashino T., Iwai Y., Eisaku H., Yakugaku Zasshi, 96, 1352-1356 (1976); b) Higashino T., Katori T., Eisaku H., ibid., 99, 1031-1036 (1979); c) Hayashi E., Shimada N., Watanabe K., ibid., 99, 205-206 (1979); d) Yamanaka H., Ohba S., Heterocycles, 31, 895-909 (1990); e) Mizuno Y., Adachi K., Ikeda K., Chem. Pharm. Bull., 2, 225-234 (1954).
22. Miyashita A., Suzuki Y., Kobayashi M., Kuriyama N., Higashino T., Heterocycles, 43, 509-512 (1996).
23. Miyashita A., Fujimoto K., Okada T., Higashino T., Heterocycles, 42, 691-699 (1996).
24. Greenberg S. M., Ross L. O., Robins R. K., J. Org. Chem., 24, 1314-1317 (1959).
25. Miyashita A., Iijima C., Higashino T., Matsuda H., Heterocycles, 31, 1309-1314 (1990).